Healthcare / BiotechnologyShanghai
$34.77
-0.85 (-2.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $46.3M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
79.0x
↑EV/EBITDA
28.9x
↑ROE
1.8%
↑Gross Margin
51.7%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.6%
FCF CAGR
—
FCF margin
12.2%
FCF / Net income
1.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $421.0M · net income $31.4M · FCF $51.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $421.0M | $421.0M | $381.2M | $366.5M | $303.0M |
| Net Income | $31.4M | $31.4M | $6.5M | $-20.6M | $-5.4M |
| EBITDA | $86.7M | $86.7M | $66.1M | $23.6M | $27.5M |
| EPS | 0.42 | 0.42 | 0.08 | -0.26 | -0.07 |
| Gross Margin | 51.7% | 51.7% | 45.6% | 42.4% | 41.7% |
| Operating Margin | 5.9% | 5.9% | -2.9% | -8.7% | -9.3% |
| Net Margin | 7.5% | 7.5% | 1.7% | -5.6% | -1.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.05 | 0.05 | 0.07 |
| Current Ratio | 5.83 | 5.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $51.3M | $51.3M | $46.3M | $-104.2M | $-251.4M |
| Returns | |||||
| ROE | 1.8% | 1.8% | 0.4% | -1.2% | -0.3% |
| Valuation | |||||
| P/E | 79.02 | 79.02 | 283.50 | — | — |
| EV/EBITDA | 28.94 | 28.94 | 25.98 | 125.90 | 132.10 |
| P/B | 1.52 | 1.52 | 1.09 | 1.71 | 2.20 |
| Growth & Yield | |||||
| Revenue Growth | 10.4% | 10.4% | 4.0% | 21.0% | — |
| EPS Growth | 425.0% | 425.0% | 130.8% | -271.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
94.4%
EPS terminal req.
$3.09
Spread vs growth
330.6%
5Y implied EPS CAGR
54.8%
EPS terminal req.
$3.73
Spread vs growth
370.2%
10Y implied EPS CAGR
30.5%
EPS terminal req.
$6.01
Spread vs growth
394.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.2%
Start / end P/E
341.6x → 82.8x
EPS bridge
0.08 → 0.42
Residual
-322.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.